Bayer’s Trasylol raises kidney risks, FDA says

Bayer AG’s Trasylol, a drug to control bleeding during heart bypass surgery, raised the risk of kidney damage in clinical studies and may increase the chance of death, according to U.S. regulators. The findings may justify restrictions on use of the injectable treatment or require new clinical trials, staff of the U.S. Food and Drug Administration ...

Enter your user name and password in the fields above to gain access to the subscriber content on this site. Need a subscription? Click here.
Your subscription includes one set of login credentials for your exclusive use. Security features have been integrated on this site: If someone signs in with your credentials while you are logged in, the site will automatically close your ongoing login and you will lose access at that time.
If you feel your login credentials are being used by a second party, contact customer service at 877-615-9536 for assistance in changing your password.

Already a paid subscriber but not registered for online access yet? For instructions on how to get premium web access, click here.

Forgot your password?

MLM Counties News. Notices. Need-to-know Information.

Bayer’s Trasylol raises kidney risks, FDA says

Leave a Reply